ARTICLE | Clinical News

Resverlogix plummets on ASSERT miss

November 18, 2010 1:39 AM UTC

Resverlogix Corp. (TSX:RVX) fell C$1.77 (39%) to C$2.73 on Wednesday after once-daily RVX-208 plus standard of care (SOC) missed the primary endpoint of significantly increasing APOA1 from baseline to week 12 vs. placebo plus SOC in the Phase II ASSERT trial to treat atherosclerosis in patients with stable coronary artery disease (CAD). SOC included the physician's choice of statin therapy. The double-blind, U.S. trial enrolled 299 patients. Data were presented at the American Heart Association meeting in Chicago. ...